​

Carisma Therapeutics (CARM) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

CARM Stock Forecast

Carisma Therapeutics (CARM) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 1100.00% increase from the last price of $0.50.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $0.5

CARM Stock Rating

Carisma Therapeutics stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 0 3 Strong Sell Sell Hold Buy Strong Buy

CARM Forecast vs Benchmarks

TypeNameUpside
StockCarisma Therapeutics1100.00%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$0.50$0.50$0.50
Upside/Downside--1100.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-14--5
Dec, 24144--9
Nov, 2435---8
Oct, 2435---8
Sep, 2434---7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 11, 2024Justin ZelinBTIG$6.00$1.91214.14%1100.00%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024EF HuttonBuyinitialise
Jun 26, 2024BTIGUnderperformUnderperformhold
May 10, 2024H.C. WainwrightBuyBuyhold
Apr 02, 2024H.C. WainwrightBuyBuyhold
Nov 30, 2022Zacks Investment ResearchBuyupgrade

Financial Forecast

EPS Forecast

$-300 $-240 $-180 $-120 $-60 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.79$-4.47$-1.98$-259.15-----
Avg Forecast$-3.87$-1.40$-3.80$-2.52$-1.20$-0.62$-0.62$-0.38$-0.38
High Forecast$-4.69$-1.70$-4.37$-2.62$-1.37$-0.75$-0.83$-0.43$-0.43
Low Forecast$-3.25$-1.18$-3.19$-2.43$-0.99$-0.49$-0.41$-0.31$-0.31
Surprise %23.77%219.29%-47.89%10183.73%-----

Revenue Forecast

$5M $13M $21M $29M $37M $45M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.24M$26.54M$40.00M$14.92M-----
Avg Forecast$11.22M$6.51M$40.00M$13.53M$21.41M$20.32M$10.00M$33.26M$9.98M
High Forecast$9.85M$5.72M$35.10M$11.40M$18.49M$17.55M$8.64M$28.72M$8.62M
Low Forecast$13.06M$7.58M$44.59M$15.65M$23.79M$22.58M$11.11M$36.96M$11.10M
Surprise %0.11%307.45%-10.27%-----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.32M$-40.77M$-19.88M$-86.88M-----
Avg Forecast$-129.63M$-46.93M$-127.39M$-86.88M$-39.57M$-20.79M$-20.79M$-12.53M$-12.74M
High Forecast$-157.16M$-56.90M$-146.38M$-87.77M$-46.05M$-25.14M$-27.83M$-14.58M$-14.58M
Low Forecast$-108.99M$-39.46M$-107.09M$-81.36M$-33.09M$-16.43M$-13.74M$-10.48M$-10.48M
Surprise %-78.15%-13.12%-84.39%------

CARM Forecast FAQ

Is Carisma Therapeutics stock a buy?

Carisma Therapeutics stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Carisma Therapeutics is a favorable investment for most analysts.

What is Carisma Therapeutics's price target?

Carisma Therapeutics's price target, set by 3 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 1100.00% change from the previous close price of $0.5.

How does Carisma Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Carisma Therapeutics stock forecast shows a 1100.00% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Carisma Therapeutics over the past three months?

  • January 2025: 0% Strong Buy, 20.00% Buy, 80.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 11.11% Strong Buy, 44.44% Buy, 44.44% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Carisma Therapeutics’s EPS forecast?

Carisma Therapeutics's average annual EPS forecast for its fiscal year ending in December is -1.2 for 2024, a -99.54% decrease from the reported $-259 in 2023. The prediction for 2025 is $-0.62, $-0.62 for 2026, $-0.38 for 2027, and $-0.38 for 2028.

What is Carisma Therapeutics’s revenue forecast?

Carisma Therapeutics's average annual revenue forecast for its fiscal year ending in December is $21.41M for 2024, a 43.51% increase from the reported $14.92M in 2023. The forecast for 2025 is $20.32M, $10M for 2026, $33.26M for 2027, and $9.98M for 2028.

What is Carisma Therapeutics’s net income forecast?

For its fiscal year ending in December, Carisma Therapeutics's average annual net income forecast is $-39.572M for 2024, reflecting a -54.45% decrease from the reported $-86.879M in 2023. The projection for 2025 is $-20.787M, $-20.785M for 2026, $-12.531M for 2027, and $-12.739M for 2028.